scholarly journals Prospective Evaluation of the Use of Lokivetmab in Dogs With Atopic Dermatitis in Brazil

2021 ◽  
Author(s):  
Millena Leme Campos ◽  
Ronaldo Lucas ◽  
Jonas Moraes-Filho ◽  
Viviani di Marco ◽  
Jessica Dinelli Lopes ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Adverse Events ◽  
Clinical Manifestations ◽  
Severity Index ◽  
Response To Treatment ◽  
Effective Response ◽  
Canine Atopic Dermatitis ◽  
Treatment Responses ◽  
E Mail ◽  
Degrees Of Severity

Abstract Background: Lokivetmab (Cytopoint®, Zoetis) is a caninized anti-IL-31 monoclonal antibody licensed for treating clinical manifestations of canine atopic dermatitis in varying degrees of severity. The objective of this 30-day prospective study was to evaluate the level of improvement in cases of atopic dermatitis after the application of lokivetmab, using the Canine Atopic Dermatitis Extent and Severity Index (CADESI-4) variables, Visual Analogue Scale (VAS) of pruritus, owner assessment of the condition, and incidence of adverse events. A total of 110 animals recruited from two private clinics in the State of São Paulo each received 2 mg of lokivetmab/kg of body weight by subcutaneous injection on day 0. Dogs were observed by owners who provided reports of their observations by telephone or e-mail on days 2 and 14 and were observed by clinicians on day 30. Results: Baseline mean VAS of pruritus was 7.68 (median = 7), decreasing to 3.82 (median = 2) by day 2 (P<0.001). CADESI-4 variables decreased from 36.5 at baseline to 16.3 on day 30 (P<0.001). Reports of treatment responses submitted by owners and evaluation of CADESI-4 variables after treatment were significantly similar (P<0.001). Owners rated the response to treatment as good to excellent for 75% of the dogs. Adverse events, including vomiting, diarrhea, and/or lethargy, were observed in 18 dogs (16.4%). All events were transient, and none required treatment. Conclusions: Based on findings in this study, lokivetmab was determined to provide a rapid and effective response for control of canine atopic dermatitis. Lokivetmab was well tolerated with only mild and transient adverse events observed.

Clinical efficacy of neural therapy for the treatment of atopic dermatitis in dogs

2008 ◽  
Vol 56 (4) ◽  
pp. 459-469 ◽  
Author(s):  
Adriana Bravo-Monsalvo ◽  
Juan Vázquez-Chagoyán ◽  
Lilia Gutiérrez ◽  
Héctor Sumano
Keyword(s):  
Atopic Dermatitis ◽  
Clinical Efficacy ◽  
Severity Index ◽  
Control Group ◽  
Matched Pairs ◽  
Neural Therapy ◽  
Canine Atopic Dermatitis ◽  
Dermatological Condition ◽  
Before And After ◽  
History Of

The aim of this trial was to assess the clinical efficacy of neural therapy (NT) when treating canine atopic dermatitis. Eighteen dogs (no control group), with at least a 12-month history of having nonseasonal atopic dermatitis, were included. No medication with either glucocorticoids or cyclosporin was allowed during the trial. One set of NT was given by injecting an intravenous dose of 0.1 mg/kg of a 0.7% procaine solution, followed by 10 to 25 intradermal injections of the same solution in a volume of 0.1–0.3 mL per site. Dogs were given 6–13 sets of NT during the therapy. The dermatological condition of each patient was evaluated before and after the treatment using two scales: the pruritus visual analogue scale (PVAS) and the canine atopic dermatitis extent and severity index (CADESI). The reduction of pruritus was statistically significant using a Wilcoxon matched-pairs signed-ranks test (P < 0.001). No adverse side effects were observed. NT seems to be an effective alternative to control signs related to canine atopic dermatitis.

The evaluation of Canine Atopic Dermatitis Extent and Severity Index (CADESI) test in dogs with Atopic Dermatitis (AD) treated with cyclosporine or prednisone

2010 ◽  
Vol 13 (4) ◽  
pp. 681-688 ◽  
Author(s):  
I. Taszkun
Keyword(s):  
Atopic Dermatitis ◽  
Severity Index ◽  
Skin Lesions ◽  
Clinical State ◽  
Point Scale ◽  
Canine Atopic Dermatitis ◽  
Group I ◽  
Oral Preparation ◽  
Sandimmun Neoral ◽  
Anti Inflammatory

The evaluation of Canine Atopic Dermatitis Extent and Severity Index (CADESI) test in dogs with Atopic Dermatitis (AD) treated with cyclosporine or prednisone The purpose of this study was to assess the clinical state of dogs with atopic dermatitis (AD) by use of CADESI test in own modification during the first visit in the Dermatology Consult Room as well as during the treatment. The study was performed in two groups (I-E and II-C) of 20 dogs in each group. In dogs which were qualified to the I-E group, as antiallergic, anti-inflammatory and antipruritic treatment, prednisone (oral preparation Encorton - Polfa Pabianice) at dose 0.5 mg/kg b.w./day was administered, while in dogs qualified to the II-C group - cyclosporine (oral preparation Sandimmun Neoral - Novartis Pharma) at a dose of 5 mg/kg b.w./day; the treatment was continued for 6 weeks in both groups. During the study, skin lesions were assessed in 15 specified body areas using 4 parameters and 5-point scale. In group I-E and II-C the amount of received points in CADESI test was decreased by 82.26% and by 83% respectively, after the treatment. Statistical analyses of the results obtained revealed no statistically significant (P=0.05) differences between means of I-E and II-C groups in consecutive examinations, which indicates comparable clinical efficacy of both drugs. Statistically significant differences (P=0.05) of the parameters assessed were found after secondary dermatoses treatment, and after every two weeks of antipruritic and anti-inflammatory treatment.

Validation of the Canine Atopic Dermatitis Extent and Severity Index (CADESI)-4, a simplified severity scale for assessing skin lesions of atopic dermatitis in dogs

2014 ◽  
Vol 25 (2) ◽  
pp. 77-e25 ◽  
Author(s):  
Thierry Olivry ◽  
Manolis Saridomichelakis ◽  
Tim Nuttall ◽  
Emmanuel Bensignor ◽  
Craig E. Griffin ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Severity Index ◽  
Skin Lesions ◽  
Severity Scale ◽  
Canine Atopic Dermatitis

Fluoxetine (SSRI) treatment of canine atopic dermatitis: a randomized, double-blind, placebo-controlled, crossover trial

2014 ◽  
Vol 17 (2) ◽  
pp. 371-373 ◽  
Author(s):  
M. Fujimura ◽  
H. Ishimaru ◽  
Y. Nakatsuji
Keyword(s):  
Atopic Dermatitis ◽  
Selective Serotonin Reuptake Inhibitors ◽  
Crossover Trial ◽  
Severity Index ◽  
Base Line ◽  
Double Blind ◽  
Canine Atopic Dermatitis ◽  
Double Blind Placebo ◽  
Significant Difference ◽  
Ssri Treatment

Abstract This study investigated effects of a fluoxetine (selective serotonin reuptake inhibitors; SSRI, 1 mg/kg) on pruritus in canine atopic dermatitis (CAD). After 4-weeks of base-line observation, 8 dogs with CAD entered a 2-months randomized, double-blind, placebo-controlled, crossover trial comparing fluoxetine with placebo. Clinical efficacy was evaluated using a Canine Atopic Dermatitis Extent and Severity Index (CADESI-03) and Pruritus Visual Analog Scale (PVAS). Six dogs completed the study [two out of eight dogs (both of them were Shiba Inu) dropped out from the study due to a depression]. CADESI-03 and PVAS between fluoxetine and placebo showed no significant difference statistically (P>0.05 and P>0.05 respectively). Fluoxetine showed no efficacy on pruritus in CAD. Further researches are needed for the treatment on pruritus of CAD

scholarly journals Spot-On Skin Lipid Complex as an Adjunct Therapy in Dogs with Atopic Dermatitis: An Open Pilot Study

2011 ◽  
Vol 2011 ◽  
pp. 1-5 ◽  
Author(s):  
Masato Fujimura ◽  
Yoshinobu Nakatsuji ◽  
Subaru Fujiwara ◽  
Christophe Rème ◽  
Hugues Gatto
Keyword(s):  
Atopic Dermatitis ◽  
Marked Reduction ◽  
Severity Index ◽  
Lipid Complex ◽  
Adjunct Therapy ◽  
Skin Lipid ◽  
Canine Atopic Dermatitis ◽  
The Third ◽  
Clinical Benefits ◽  
Open Pilot

The purpose of this paper was to evaluate the efficacy of topical skin lipid complex (SLC) in canine atopic dermatitis (AD). Eight dogs with chronic AD and no improvement of main therapy in symptoms, erythema, lichenification, excoriation, and alopecia in the previous month were treated with SLC topically as adjunct therapy at lesion sites twice weekly for 12 weeks. A statistically significant reduction (26.0%, ) in the third version of the Canine Atopic Dermatitis Extent and Severity Index (CADESI-03) modification from baseline was recorded 6 weeks after treatment, with marked reduction in the erythema subscore (36.2%, ). A significant reduction in excoriation and alopecia subscores was observed 6 weeks after treatment (39.9%, and 19.9%, , resp.). However, the lichenification subscore was not reduced significantly at 6 or 12 weeks. These findings suggest that topical SLC may have therapeutic and clinical benefits in dogs with AD.

The Influence of Topical Unsaturated Fatty Acids and Essential Oils on Normal and Atopic Dogs

2011 ◽  
Vol 47 (4) ◽  
pp. 236-240 ◽  
Author(s):  
Sandra Tretter ◽  
Ralf S. Mueller
Keyword(s):  
Fatty Acids ◽  
Atopic Dermatitis ◽  
Essential Oils ◽  
Unsaturated Fatty Acids ◽  
Severity Index ◽  
Transepidermal Water Loss ◽  
Closed Chamber ◽  
Canine Atopic Dermatitis ◽  
Significant Difference ◽  
Before And After

Seven dogs with atopic dermatitis and six normal dogs were treated with a spot-on product containing essential oils and unsaturated fatty acids q 7 days for 8 wk. Seven additional atopic dogs received a daily spray containing similar ingredients to the spot-on. In all dogs, transepidermal water loss (TEWL) was measured before and after treatment using a closed chamber device. In atopic dogs, a validated lesion score (canine atopic dermatitis extent and severity index, CADESI) was determined and pruritus was assessed with a visual analog scale before and after treatment. The mean CADESI scores in atopic dogs decreased with the spot-on (P=0.0043) and with the spray (P=0.0366). Similarly, the pruritus scores decreased with the spot-on (P=0.266) and with the spray (P=0.0177). There was a significant difference between the TEWL values of healthy and atopic dogs on the abdomen (P=0.0181) and back (P=0.0123). TEWL decreased significantly on the back after treatment with the spray (P=0.016), but not on the abdomen (P=0.078). Adverse effects were not observed. The results of this pilot study indicate that topical fatty acids and essential oils are a useful treatment option for canine atopic dermatitis.

scholarly journals Effects of Feeding a Hypoallergenic Diet with a Nutraceutical on Fecal Dysbiosis Index and Clinical Manifestations of Canine Atopic Dermatitis

Animals ◽  
2021 ◽  
Vol 11 (10) ◽  
pp. 2985
Author(s):  
Eleonora Elisa Alice Guidi ◽  
Alessandro Gramenzi ◽  
Paola Persico ◽  
Roberta Di Prinzio ◽  
Daniele Di Simone ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Gastrointestinal Tract ◽  
Multimodal Treatment ◽  
Clinical Manifestations ◽  
Skin Lesions ◽  
Cutaneous Lesions ◽  
Dietary Regimen ◽  
Canine Atopic Dermatitis ◽  
Intestinal Dysbiosis ◽  
Allergic Skin

Background: an imbalance of the intestinal microbiota can cause health problems in the gastrointestinal tract and in other organs. Canine Atopic Dermatitis (CAD) is a genetically predisposed, inflammatory and pruritic allergic skin disease with multifactorial etiology and multimodal treatment. The aim of this study was to assess the effect of a nutraceutical product on Dysbiotic Index (DI) and the skin lesions of atopic dogs. Methods: a nutraceutical product was administered to 32 dogs with CAD. The product was associated with a standardized hypoallergenic diet for 60 days; the dietary regimen continued for 120 days, while ongoing therapies remained unchanged. Values of Visual Analogic Scale (VAS), Canine Atopic Dermatitis Lesional Index (CADLI) and DI were evaluated on day 0, 60, 120. Results: all the 32 dogs showed a statistically significant decrease (p < 0.001) to V60 of VAS and CADLI, which persisted and increased to V120 when diet alone was continued. The decrease in the DI value was also statistically significant (p < 0.001). Conclusion: the intake of nutraceutical associated with diet resulted in a decrease in the index of intestinal dysbiosis, with an improvement in the subjective severity of cutaneous lesions.

Allogeneic adipose-derived mesenchymal stem cell therapy in dogs with refractory atopic dermatitis: clinical efficacy and safety

2018 ◽  
Vol 183 (21) ◽  
pp. 654-654 ◽  
Author(s):  
Antonio José Villatoro ◽  
Manuel Hermida-Prieto ◽  
Viviana Fernández ◽  
Fernando Fariñas ◽  
Cristina Alcoholado ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Global Assessment ◽  
Clinical Signs ◽  
Severity Index ◽  
Positive Outcome ◽  
Efficacy And Safety ◽  
Promising Alternative ◽  
Canine Atopic Dermatitis ◽  
Mesenchymal Stem Cell Therapy ◽  
Common Skin

Canine atopic dermatitis (AD) is a common skin disease with a 10–15 per cent prevalence. Current treatments vary in their efficacy and safety. The immunomodulatory properties of mesenchymal stem cells (MSCs) make them a promising alternative treatment. The aim of this study was to evaluate the therapeutic efficacy and safety of allogeneic canine adipose MSCs (cAd-MSCs) in dogs with refractory AD. Twenty-six dogs, suffering from AD for at least 12 months, not responding to conventional therapy, received an intravenous dose of 1.5×106 cAd-MSCs/kg bodyweight. Clinical signs, haematological and biochemistry profiles, and AD severity were assessed in a six-month follow-up using a validated scoring system (Canine Atopic Dermatitis Extent and Severity Index, version 4 (CADESI-04)). The degree of pruritus was quantified using a validated visual analogue scale, and also owner’s global assessment of treatment efficacy. Twenty-two animals completed the study. Pruritus and CADESI-04 scores decreased significantly after one week or month of treatment, respectively, and remained stable for six months. Owner’s global assessment score was 2.15±1.15 for all the animals in the study. In conclusion, systemic administration of allogeneic cAd-MSCs appeared to be a simple therapy with positive outcome in the remission of clinical signs for AD refractory to conventional medications, for at least six months and with no adverse events.

scholarly journals Application of Janus Kinase Inhibitors in Atopic Dermatitis: An Updated Systematic Review and Meta-Analysis of Clinical Trials

2021 ◽  
Vol 11 (4) ◽  
pp. 279
Author(s):  
Hou-Ren Tsai ◽  
Jing-Wun Lu ◽  
Li-Yu Chen ◽  
Tai-Li Chen
Keyword(s):  
Atopic Dermatitis ◽  
Adverse Events ◽  
Kinase Inhibitors ◽  
Rating Scale ◽  
Numerical Rating Scale ◽  
Meta Analysis ◽  
Severity Index ◽  
Janus Kinase ◽  
Drug Discontinuation ◽  
Jak Inhibitors

Janus kinase (JAK) inhibitors are promising treatments for atopic dermatitis (AD). The aim of this study was to assess the efficacy and safety of JAK inhibitors for AD treatment via the “Grading of Recommendations Assessment, Development, and Evaluation” approach. We identified 15 randomized controlled trials comparing oral or topical JAK inhibitors against placebo to treat AD. A random-effects meta-analysis was performed, and the numbers-needed-to-treat (NNTs)/numbers-needed-to-harm (NNHs) were calculated. Patients treated with JAK inhibitors were associated with higher rates of achieving eczema area and severity index-75 (rate ratio (RR): 2.84; 95% confidence interval (CI): 2.20–3.67; I2: 38.9%; NNT = 3.97), Investigator’s Global Assessment response (RR: 2.99; 95% CI: 2.26–3.95; I2: 0%; NNT = 5.72), and pruritus numerical rating scale response (RR: 2.52; 95% CI: 1.90–3.35; I2: 39.4%; NNT = 4.91) than those treated with placebo. Moreover, patients treated with JAK inhibitors had a higher risk of treatment-emergent adverse events (RR: 1.14; 95% CI: 1.02–1.28; I2: 52%; NNH = 14.80) but not adverse events leading to drug discontinuation. According to the evidence-based results, JAK inhibitors are potentially effective strategies (certainty of evidence: “moderate”) for treating AD with tolerable side effects (certainty of evidence: “low”). Nevertheless, long-term follow-up is required.

scholarly journals Efficacy of Dupilumab on Different Phenotypes of Atopic Dermatitis: One-Year Experience of 221 Patients

2020 ◽  
Vol 9 (9) ◽  
pp. 2684
Author(s):  
Simona Tavecchio ◽  
Luisa Angileri ◽  
Francesco Pozzo Giuffrida ◽  
Francesca Germiniasi ◽  
Angelo Valerio Marzano ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Atopic Dermatitis ◽  
Rating Scale ◽  
Numerical Rating Scale ◽  
Clinical Manifestations ◽  
Life Quality ◽  
Daily Practice ◽  
Severity Index ◽  
Efficacy And Safety

Background: The clinical features of adult-onset atopic dermatitis (AD) are heterogeneous and the diagnosis can be a challenge. A new biologic drug (dupilumab) has been approved for moderate to severe AD in adult patients. The efficacy and safety have been demonstrated in clinical trials, but these studies do not reflect conditions in daily practice and do not consider the different clinical manifestations of AD. Objectives: Analyzing the dupilumab activity in a real-world setting and comparing its efficacy on different AD phenotypes. Methods: We retrospectively evaluated 221 AD patients treated with dupilumab, stratified into six clinical phenotypes: classic, generalized eczema inflammatory and lichenoid patterns, prurigo, nummular eczema, and erythroderma. At baseline and at weeks 4, 16, and 52, the disease severity was assessed through the Eczema Area and Severity Index (EASI) and the quality of life was assessed through the Dermatology Life Quality Index (DLQI) questionnaire, Peak Pruritus Numerical Rating Scale (itch NRS), and Peak Sleep NRS. Results: We found a significant improvement after 16 weeks of treatment (p < 0.0001) in all six phenotypes for all the assessed scores mentioned above, persisting up to week 52. The best improvement was seen in the more severe phenotypes, particularly the erythrodermic one. Conclusions: The present study confirmed the efficacy and safety of dupilumab in the treatment of severe AD. Its strength was in the stratification of AD patients in six different phenotypes based on their clinical presentation, all of whom markedly improved in terms of both clinically evident and reported symptoms, as well as their quality of life.

Sign in / Sign up

Export Citation Format

Share Document